Capricor Therapeutics, Inc. (CAPR)
|Net Income (ttm)||-22.69M|
|Day's Range||4.50 - 4.60|
|52-Week Range||2.56 - 5.85|
|Price Target||15.30 (+239.2%)|
|Earnings Date||Aug 11, 2022|
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company al... [Read more...]
In 2021, CAPR's revenue was $244,898, a decrease of -21.06% compared to the previous year's $310,250. Losses were -$20.02 million, 46.6% more than in 2020.Financial Statements
According to 8 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 239.25% from the latest price.
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022...
Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session
Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatme...
-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of CAP-1002 for Duchenne Muscular Dystrophy in the United States-
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatm...
Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said...
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 ...
-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated-
The Lancet Publishes Positive Results from Capricor Therapeutics' Phase 2 Study Evaluating CAP-1002 in Late-Stage Duc...
-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients-
Capricor Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
CAP-1002 Cell Therapy Programs
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on M...
Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET
Dr. Paulson Will Lead Clinical Efforts Focused on Capricor's Late-Stage Cell Therapy Program and its Expanding Exosome Platform-- Dr. Paulson Will Lead Clinical Efforts Focused on Capricor's Late-Stage ...
Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution ...
KYOTO, Japan, Jan. 25, 2022 /PRNewswire/ -- *NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a reference.
Capricor Therapeutics Inc (NASDAQ: CAPR) has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricor's CAP-1002 for Duchenne muscular dystrophy ...
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1...
-Partnership Leverages Nippon Shinyaku's Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.-
Forget undervalued stocks, there is room for upside even in stocks with rising P/E.
Capricor's Exosome-based mRNA Vaccine for SARS-CoV-2 -In-Vivo Preclinical Data Published in the Journal of Biological Chemistry - -Preclinical Data Demonstrates Strong T-Cell Response for High Conserved...
Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...
– The Global, Virtual Event in Partnership with Genetic Engineering News (GEN) and the CRISPR Journal, Taking Place on November 16, 2021 – – The Global, Virtual Event in Partnership with Genetic Enginee...
Capricor (CAPR) delivered earnings and revenue surprises of 22.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the W...
Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET
Capricor Therapeutics Inc (NASDAQ: CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD). The trial met its primary efficacy endp...
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular ...
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–